113 related articles for article (PubMed ID: 36842751)
21. Epirubicin loaded super paramagnetic iron oxide nanoparticle-aptamer bioconjugate for combined colon cancer therapy and imaging in vivo.
Jalalian SH; Taghdisi SM; Shahidi Hamedani N; Kalat SA; Lavaee P; Zandkarimi M; Ghows N; Jaafari MR; Naghibi S; Danesh NM; Ramezani M; Abnous K
Eur J Pharm Sci; 2013 Oct; 50(2):191-7. PubMed ID: 23835028
[TBL] [Abstract][Full Text] [Related]
22. Development of pharmaceutically scalable inhaled anti-cancer nanotherapy - Repurposing amodiaquine for non-small cell lung cancer (NSCLC).
Parvathaneni V; Kulkarni NS; Chauhan G; Shukla SK; Elbatanony R; Patel B; Kunda NK; Muth A; Gupta V
Mater Sci Eng C Mater Biol Appl; 2020 Oct; 115():111139. PubMed ID: 32600728
[TBL] [Abstract][Full Text] [Related]
23. Development and in vitro evaluation of core-shell type lipid-polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancer.
Mandal B; Mittal NK; Balabathula P; Thoma LA; Wood GC
Eur J Pharm Sci; 2016 Jan; 81():162-71. PubMed ID: 26517962
[TBL] [Abstract][Full Text] [Related]
24. Nanotechnology Based Repositioning of an Anti-Viral Drug for Non-Small Cell Lung Cancer (NSCLC).
Parvathaneni V; Goyal M; Kulkarni NS; Shukla SK; Gupta V
Pharm Res; 2020 Jun; 37(7):123. PubMed ID: 32514688
[TBL] [Abstract][Full Text] [Related]
25. Preparation, characterization and evaluation of antibacterial properties of epirubicin loaded PHB and PHBV nanoparticles.
Perveen K; Masood F; Hameed A
Int J Biol Macromol; 2020 Feb; 144():259-266. PubMed ID: 31821825
[TBL] [Abstract][Full Text] [Related]
26. Lipid nanoparticle-based co-delivery of epirubicin and BCL-2 siRNA for enhanced intracellular drug release and reversing multidrug resistance.
Yu M; Han S; Kou Z; Dai J; Liu J; Wei C; Li Y; Jiang L; Sun Y
Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):323-332. PubMed ID: 28393563
[TBL] [Abstract][Full Text] [Related]
27. Development of inhalable quinacrine loaded bovine serum albumin modified cationic nanoparticles: Repurposing quinacrine for lung cancer therapeutics.
Vaidya B; Kulkarni NS; Shukla SK; Parvathaneni V; Chauhan G; Damon JK; Sarode A; Garcia JV; Kunda N; Mitragotri S; Gupta V
Int J Pharm; 2020 Mar; 577():118995. PubMed ID: 31935471
[TBL] [Abstract][Full Text] [Related]
28. Smart delivery of epirubicin to cancer cells using aptamer-modified ferritin nanoparticles.
Yazdian-Robati R; Bayat P; Dehestani S; Hashemi M; Taghdisi SM; Abnous K
J Drug Target; 2022 Jun; 30(5):567-576. PubMed ID: 34991424
[TBL] [Abstract][Full Text] [Related]
29. Pullulan acetate nanoparticles prepared by solvent diffusion method for epirubicin chemotherapy.
Zhang HZ; Gao FP; Liu LR; Li XM; Zhou ZM; Yang XD; Zhang QQ
Colloids Surf B Biointerfaces; 2009 Jun; 71(1):19-26. PubMed ID: 19186037
[TBL] [Abstract][Full Text] [Related]
30. Self-assembly of DNA nanostructure containing cell-specific aptamer as a precise drug delivery system for cancer therapy in non-small cell lung cancer.
Wang N; Yu C; Xu T; Yao D; Zhu L; Shen Z; Huang X
J Nanobiotechnology; 2022 Nov; 20(1):486. PubMed ID: 36403038
[TBL] [Abstract][Full Text] [Related]
31. Poly-(Lactic-co-Glycolic) Acid Nanoparticles for Synergistic Delivery of Epirubicin and Paclitaxel to Human Lung Cancer Cells.
Sharma N; Kumari RM; Gupta N; Syed A; Bahkali AH; Nimesh S
Molecules; 2020 Sep; 25(18):. PubMed ID: 32947799
[TBL] [Abstract][Full Text] [Related]
32. Anthracyclines in non-small cell lung cancer.
Pronzato P; Vigani A; Tognoni A; Vaira F; Canessa P
Lung Cancer; 2001 Dec; 34 Suppl 4():S57-9. PubMed ID: 11742704
[TBL] [Abstract][Full Text] [Related]
33. Co-Delivery of Epirubicin and siRNA Using Functionalized Mesoporous Silica Nanoparticles Enhances In vitro and In vivo Drug Efficacy.
Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Abnous K; Malaekeh-Nikouei B
Curr Drug Deliv; 2016; 13(7):1176-1182. PubMed ID: 26718488
[TBL] [Abstract][Full Text] [Related]
34. Differences in Transport Characteristics and Cytotoxicity of Epirubicin and Doxorubicin in HepG2 and A549 Cells.
Nagai K; Fukuno S; Shiota M; Tamura M; Yabumoto S; Konishi H
Anticancer Res; 2021 Dec; 41(12):6105-6112. PubMed ID: 34848465
[TBL] [Abstract][Full Text] [Related]
35. In-vitro evaluation of copper/copper oxide nanoparticles cytotoxicity and genotoxicity in normal and cancer lung cell lines.
Fahmy HM; Ebrahim NM; Gaber MH
J Trace Elem Med Biol; 2020 Jul; 60():126481. PubMed ID: 32135445
[TBL] [Abstract][Full Text] [Related]
36. Phase I-II study of high-dose epirubicin in advanced non-small-cell lung cancer.
Feld R; Wierzbicki R; Walde PL; Shepherd FA; Evans WK; Gupta S; Shannon P; Lassus M
J Clin Oncol; 1992 Feb; 10(2):297-303. PubMed ID: 1310105
[TBL] [Abstract][Full Text] [Related]
37. Development, optimization and in vitro evaluation of oxaliplatin loaded nanoparticles in non-small cell lung cancer.
Esim O; Bakirhan NK; Yildirim N; Sarper M; Savaser A; Ozkan SA; Ozkan Y
Daru; 2020 Dec; 28(2):673-684. PubMed ID: 33089432
[TBL] [Abstract][Full Text] [Related]
38. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.
Plosker GL; Faulds D
Drugs; 1993 May; 45(5):788-856. PubMed ID: 7686469
[TBL] [Abstract][Full Text] [Related]
39. Terfenadine combined with epirubicin impedes the chemo-resistant human non-small cell lung cancer both in vitro and in vivo through EMT and Notch reversal.
An L; Li DD; Chu HX; Zhang Q; Wang CL; Fan YH; Song Q; Ma HD; Feng F; Zhao QC
Pharmacol Res; 2017 Oct; 124():105-115. PubMed ID: 28754458
[TBL] [Abstract][Full Text] [Related]
40. Development of paclitaxel loaded pegylated gelatin targeted nanoparticles for improved treatment efficacy in non-small cell lung cancer (NSCLC): an in vitro and in vivo evaluation study.
Gu M; Luan J; Song K; Qiu C; Zhang X; Zhang M
Acta Biochim Pol; 2021 Aug; 68(4):583-591. PubMed ID: 34355554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
